Investigational drug · Phase 3
TQB3909
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Small Lymphocytic Lymppho, Relapsed/Refractory Chronic Lymphocytic Leukemia, Myeloid Malignancy.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
9
Any phase or sponsor naming "TQB3909"
First trial start
2024
Apr 17, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQB3909", any sponsor or status.
Conditions studied
As listed on its trial records.
- Small Lymphocytic Lymppho
- Relapsed/Refractory Chronic Lymphocytic Leukemia
- Myeloid Malignancy
Approved drugs for the same conditions: Chronic lymphocytic leukemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "TQB3909" as an intervention, largest first.
- A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic MalignancyStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06211751 · 208 participants (planned) · Start Jan 2024 · Primary completion Dec 2025
Drug: TQB3909 tablets; TQB3702 tablets · For: Hematologic Malignancy
Sites: Zhengzhou, China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07011186 · 138 participants (planned) · Start Apr 17, 2024 · Primary completion Oct 2025
Drug: TQB3909 Tablets + Azacitidine · For: Myeloid Malignancy
Sites: Bengbu, China; Beijing, China; Chengde, China · 21 sites in all
- A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Pivotal-lookingNot yet recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07753369 · 128 participants (planned) · Start Aug 2026 · Primary completion Dec 2030
Drug: TQB3909 Tablets; Bendamustine Injection and 2 more · For: Small Lymphocytic Lymppho; Relapsed/Refractory Chronic Lymphocytic Leukemia
Sites: Zhengzhou, China; Nanjing, China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04975204 · 126 participants (planned) · Start Feb 18, 2022 · Primary completion Dec 2022
Drug: TQB3909 Tablets · For: Advanced Malignant Tumor
Sites: Nanjing, China; Tianjin, China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05959694 · 107 participants (planned) · Start Oct 11, 2023 · Primary completion Dec 2025
Drug: TQB3909 tablet · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Anqing, China; Wuwei, China; Guangzhou, China · 25 sites in all
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05775575 · 65 participants (planned) · Start Mar 2, 2023 · Primary completion Dec 2023
Drug: TQB3909 tablets · For: Advanced Breast Cancer
Sites: Changsha, China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06165822 · 40 participants (planned) · Start Dec 2023 · Primary completion Jan 2024
Drug: TQB3909 tablets; Itraconazole capsule and 1 more · For: Advanced Malignant Neoplasm
Sites: Changzhou, China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06245941 · 21 participants · Start May 13, 2024 · Primary completion Dec 30, 2025
Drug: TQ05105 tablets; TQB3909 tablets · For: Myelofibrosis
Sites: Hefei, China; Zhengzhou, China; Xi'an, China · 5 sites in all
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT06106841 · 19 participants · Start Oct 5, 2023 · Primary completion Oct 16, 2024
Drug: 400mg of TQB3909 tablets; 600mg of TQB3909 tablets · For: Mantle Cell Lymphoma
Sites: Beijing, China; Chongqing, China; Xiamen, China · 28 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Prediction of CYP3A4-mediated drug-drug interactions of a novel Bcl-2 inhibitor TQB3909 using physiologically based pharmacokinetic modeling.
Chen H, Zhu S, Yang A, et al. · Cancer Chemother Pharmacol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.